BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//c-myc - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:c-myc
X-ORIGINAL-URL:https://cmyc.w.uib.no
X-WR-CALDESC:Events for c-myc
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Oslo
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Oslo:20250821T101500
DTEND;TZID=Europe/Oslo:20250821T140000
DTSTAMP:20260528T130954
CREATED:20250819T123626Z
LAST-MODIFIED:20250819T124431Z
UID:689-1755771300-1755784800@cmyc.w.uib.no
SUMMARY:Master's Degree Examination for Stine Haugstvedt
DESCRIPTION:Stine Haugstvedt will present and defend her Master’s thesis: \n“Optimizing single-cell and immune profiling of asciminib-treated chronic myeloid leukemia patients using mass cytometry” \n\nDate: Thursday\, August 21\nTime: 10:15 AM\nLocation: Birkhaugsalen\, D305\, 3rd floor\, Central Block\, Haukeland University Hospital\n\nSupervisors: \n\nAssoc. Prof. Morten Beck Rye (NTNU)\nProf. Bjørn Tore Gjertsen (UiB)\nDr. Stein-Erik Gullaksen (UiB)\n\nInternal Examiner: Prof. Berit Johansen (NTNU)\nExternal Examiner: Dr. David Micklem (BerGenBio) \nPresentations Following the Master’s Examination \n\n13:00 –Assoc. Prof. Morten Beck Rye\, Dept. of Clinical and Molecular Medicine\, NTNU\nSpatial Transcriptomics Analysis of Prostate Cancer\n13:20 –Prof. Berit Johansen\, Dept. of Biology\, NTNU\nTreating cancer and leukemia: A new way to trigger cell self-destruction
URL:https://cmyc.w.uib.no/event/masters-degree-examination-for-stine-haugstvedt/
LOCATION:Birkhaugsalen (D303)\, 3rd floor\, Central Block\, Haukeland University Hospital
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Oslo:20250821T130000
DTEND;TZID=Europe/Oslo:20250821T140000
DTSTAMP:20260528T130954
CREATED:20250825T082049Z
LAST-MODIFIED:20250825T082049Z
UID:738-1755781200-1755784800@cmyc.w.uib.no
SUMMARY:c-myc Seminar
DESCRIPTION:13:00 –Assoc. Prof. Morten Rye\, Dept. of Clinical and Molecular Medicine\, NTNU: Spatial Transcriptomics Analysis of Prostate Cancer \nThe cancerous prostate gland is a heterogenous mix of different cancer and normal cells and tissue types\, which is a major source of confounding when large scale molecular – omics analysis is performed on the prostate gland. One way to delineate this heterogeneity is Spatial Transcriptomics\, which can generate individual tissue specific gene expression profiles from thousands of spots placed on a grid across a prostate cancer tissue slice (see illustration). A major clinical challenge in prostate cancer is the ability to distinguish aggressive and non-aggressive prostate cancer in the cancer care pathway\, and Spatial Transcriptomics could be a technology to do more precise molecular diagnostics of prostate cancer. With this in mind\, our Prostomics research group generated spatial transcriptomics datasets (Visium 10x Genomics) on 32 tissue samples from 8 prostate cancer patients\, 5 containing aggressive and 3 containing non- aggressive cancers. Samples were taken specifically from cancer\, cancer-adjacent and distant normal tissue regions\, and spots where classified according to their content of cancer\, extracellular matrix/stroma and normal tissue\, and further analysed by Gene Set Enrichment Analysis. Our analysis discovered that normal appearing tissue adjacent to aggressive cancer regions lose prostate specific functions and adapt properties resembling cell-types which are not expected to be present in a healthy prostate gland. \n  \n13:20 –Prof. Berit Johansen\, Dept. of Biology\, NTNU: Treating cancer and leukemia: A new way to trigger cell self-destruction \nThe polyunsaturated fatty acid arachidonic acid (AA) and its metabolites\, eicosanoids\, i.e. prostaglandins\, thromboxanes\, leukotrienes\, etc.\, have attracted considerable interest in relation to inflammatory processes and diseases\, including cancer (leukemia)\, cardiovascular and autoimmune diseases\, and metabolic disorders. AA is generated by the action of phospholipase A2 (PLA2)\, which catalyzes its hydrolytic cleavage from membrane glycerophospholipids. PLA2 enzymes constitute a superfamily of enzymes\, divided into many groups and subgroups. Among them\, cytosolic Group IVA PLA2 (cPLA2α) plays a critical role in the release of AA and is the most well-studied PLA2 in inflammation. Targeting eicosanoid production by inhibiting cPLA2α offers a promising approach for inflammation or cancer therapy. Our findings imply cPLA2α may support cancer by mitigating oxidative stress and inhibiting tumor suppressor expression suggesting that the very specific and sensitive cPLA2α -inhibitors we have developed\, has potential for treating acute leukemias and other cancers by introducing programmed cell death.
URL:https://cmyc.w.uib.no/event/c-myc-seminar/
LOCATION:Birkhaugsalen (D303)\, 3rd floor\, Central Block\, Haukeland University Hospital
END:VEVENT
END:VCALENDAR